FIDAS-5|cas:1391934-98-7|西域试剂

FIDAS-5,98.88%

产品编号：Bellancom-136144| CAS NO：1391934-98-7| 分子式：C₁₅H₁₃ClFN| 分子量：261.72

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136144	￥1450.00	杭州北京（现货）
Bellancom-136144	￥2450.00	杭州北京（现货）
Bellancom-136144	￥6500.00	杭州北京（现货）
Bellancom-136144	￥9500.00	杭州北京（现货）
Bellancom-136144	￥13500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FIDAS-5

产品介绍

FIDAS-5 是一种有效的口服活性的甲硫氨酸腺苷转移酶 2A (MAT2A) 抑制剂，IC₅₀ 为 2.1 μM。FIDAS-5 与 S-腺苷甲硫氨酸 (SAM) 有效竞争 MAT2A 结合，并具有抗癌活性。

生物活性

FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities.

体外研究

FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.
FIDAS-5 (3 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells. And FIDAS-5 induces the expression of cell cycle inhibitor, p21^WAF1/CIP1.
FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	LS174T colorectal cancer (CRC) cells
Concentration:	3 μM
Incubation Time:	7 days
Result:	Significantly inhibited the proliferation of LS174T cells.

体内研究
(In Vivo)

FIDAS-5 (20 mg/kg; oral gavage; daily; for two weeks; athymic nude mice) treatment significantly inhibits the growth of xenograft tumors, with minimal difference in body weight.
Mice are treated with FIDAS-5 (20 mg/kg) for 1 week. The liver SAM levels are significantly reduced.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	16 athymic nude mice injected with HT29 CRC cells
Dosage:	20 mg/kg
Administration:	Oral gavage; daily; for two weeks
Result:	Significantly inhibited the growth of xenograft tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	16 athymic nude mice injected with HT29 CRC cells
Dosage:	20 mg/kg
Administration:	Oral gavage; daily; for two weeks
Result:	Significantly inhibited the growth of xenograft tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	16 athymic nude mice injected with HT29 CRC cells
Dosage:	20 mg/kg
Administration:	Oral gavage; daily; for two weeks
Result:	Significantly inhibited the growth of xenograft tumors.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (477.61 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.8209 mL	19.1044 mL	38.2088 mL
5 mM	0.7642 mL	3.8209 mL	7.6418 mL
10 mM	0.3821 mL	1.9104 mL	3.8209 mL

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (7.95 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.95 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.95 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.95 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明